Autopsy report · NCT03307603

Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer

“Sponsor chose not to continue”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

Case Comprehensive Cancer Center

Sponsor type

University, hospital or other

Conditions

Metastatic Colorectal Cancer

Interventions

yttrium-90 radioembolization; Phase Ib - nivolumab; Phase II - nivolumab

Participants

0

Trials that died the same way

• SURF, Neurodevelopment, Growth Study in SGA Infants
  “Sponsor decision stopped in June 2017” (81% match in meaning)
• Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC
  “stopped by sponsor” (80% match in meaning)
• Evaluating Return to Continence and Potency Following Radical Prostatectomy
  “The sponsor decided to not move forward with this study” (80% match in meaning)
• An Exploratory Investigation to Assess Changes in Quality of Life for Individuals With Type 2 Diabetes After Taking a Meal-replacement Shake.
  “Sponsor withdrawn” (80% match in meaning)
• Patient Perception of MultiPulse Therapy™ (MPT™)
  “Sponsor ceased operations” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.